David Maxwell Kleinman, M.D., M.B.A.

David M. Kleinman, MD, MBA, FACS is a board certified ophthalmologist with fellowship training in vitreoretinal surgery. Dr. Kleinman received his medical degree with honors and completed a subsequent residency in ophthalmology at the University of Colorado School of Medicine. He then received additional training through a fellowship in vitreoretinal surgery at the University of Toronto School of Medicine. Dr. Kleinman is the former Chief of Ophthalmology at Denver Health Medical Center in Denver, Colorado where he also served as Director of Ophthalmic Trauma Services and Assistant Professor of Ophthalmology at the Rocky Mountain Lions Eye Institute.

Besides attending to his clinical practice at the University of Rochester Eye Institute, Dr. Kleinman is President and Co-founder of Eyeon Therapeutics, Inc. a start-up firm developing new treatments for eye diseases. He also serves as a consultant to both large and small ophthalmic pharmaceutical and device companies nationally.

Dr. Kleinman's research involves the pharmaceutical treatment of diabetic retinopathy and age related macular degeneration. He has made numerous contributions to clinical and research publications in national and international journals of ophthalmology, and has made presentations throughout the world. In addition, he participated as a surgeon for the Himalayan Cataract Project and served as a staff ophthalmologist for Project ORBIS International, Inc.

National Clinical Trials involve VEGF trap treatment for age related macular degeneration and Age related eye disease study 2.

Retina research trials involve Adaptive Optics Imaging of Inherited Macular Diseases.

Research